Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer

Figure 5 Duplex CRISPR/Cas9 ribonucleoprotein nanomedicine disrupted antigen-presentation cells and KRAS expression to treat colorectal cancer. A: Schematic illustration of preparation of nanoformulations; B: Disruption of antigen-presentation cells and KRAS expression after duplex HAPD/RNP treatment; C: In vivo luciferase expression of orthotopic CRC (left), and representative intestine images and H&E staining of intestine sections after nanomedicine treatment. Citation: Wan T, Pan Q, Liu C, Guo J, Li B, Yan X, Cheng Y, Ping Y. A Duplex CRISPR-Cas9 Ribonucleoprotein Nanomedicine for Colorectal Cancer Gene Therapy. Nano Lett 2021; 21: 9761-9771[270]. Copyright ©The Author(s) 2021. Reprinted permission from ACS Publications. The authors have obtained the permission for figure using from the ACS Publications (Supplementary material).